Thanks for the link. I've registered and there is a lot of good stuff. I'll still have to wait for the Dec edition of 'Hepatology' for more detailed info.
Obviously, Rx length is still an unknown for the new DAA's e.g. Sofosbuvir. It was interesting to read that only 62% of Geno 1 patients treated with 6 weeks of Sofos/Peg/Riba, went on to SVR. Those treated for 8 and 12 weeks had much higher rates of SVR.
It is worth thanking those brave patients who are trialling these drugs. It would be devastating to relapse after a short Rx course, knowing that an extra 2 or 6 weeks of Rx would have led to SVR.
I am confused about the RAV issue with Sofosbuvir. All patients were Undet. after 4 weeks of the 6 week Trial above, but relapsed after EOT. Why? Gilead state that no S282T RAV's were found in the patients that relapsed. Are there other unknown Sofosbuvir RAV's? If Sofosbuvir is so resistant to RAV's, after the virus is Undetected how does it reappear? Rx duration is going to be a big question mark. It is understandable to want the shortest (cheapist) Rx duration, and this appears to be working towards 12 weeks.
Merck are still very much in the running. Victrelis was well priced, so they may end up being the best 'cheap' option.
By now most of the members might have read some of the reports / abstracts coming out of the Nov. 1-5 meetings in Washington D.C.
Their is a lot of ways to learn about the latest research and trial results I ran across this link from the AASLD web site, it has videos from some Doctors discussing topics that is short.
Hi Matt,
Thanks for the link. I've registered and there is a lot of good stuff. I'll still have to wait for the Dec edition of 'Hepatology' for more detailed info.
Obviously, Rx length is still an unknown for the new DAA's e.g. Sofosbuvir. It was interesting to read that only 62% of Geno 1 patients treated with 6 weeks of Sofos/Peg/Riba, went on to SVR. Those treated for 8 and 12 weeks had much higher rates of SVR.
It is worth thanking those brave patients who are trialling these drugs. It would be devastating to relapse after a short Rx course, knowing that an extra 2 or 6 weeks of Rx would have led to SVR.
I am confused about the RAV issue with Sofosbuvir. All patients were Undet. after 4 weeks of the 6 week Trial above, but relapsed after EOT. Why? Gilead state that no S282T RAV's were found in the patients that relapsed. Are there other unknown Sofosbuvir RAV's? If Sofosbuvir is so resistant to RAV's, after the virus is Undetected how does it reappear? Rx duration is going to be a big question mark. It is understandable to want the shortest (cheapist) Rx duration, and this appears to be working towards 12 weeks.
Merck are still very much in the running. Victrelis was well priced, so they may end up being the best 'cheap' option.
http://www.medpagetoday.com/MeetingCoverage/AASLD/42708
Hello all
By now most of the members might have read some of the reports / abstracts coming out of the Nov. 1-5 meetings in Washington D.C.
Their is a lot of ways to learn about the latest research and trial results I ran across this link from the AASLD web site, it has videos from some Doctors discussing topics that is short.
Follow this link to see. http://www.medpagetoday.com/AASLDRapidResponseVideo/clinical-context/HepatitisC-Videos/309
Their is hundreds of Hep-C articles to read from on all kinds of interesting topics, you may have to register but it's worth it.
Matt